MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed an end of phase 2 meeting with the United States Food and Drug Administration (“FDA”) for Qnexa™. Qnexa is the company’s investigational product candidate in development for the treatment of obesity.
